Cite

HARVARD Citation

    Phillips, E. et al. (2019). Toxicity and efficacy of alemtuzumab combined with CHOP for aggressive T-cell lymphoma: a phase 1 dose-escalation trial. Leukemia & lymphoma. 60 (9), pp. 2291-2294. [Online]. 
  
Back to record